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This issue of the British Journal of Cance rcontains two related
papers addressing the feasibility of increasing the intensity of
adjuvant chemotherapy by increasing the frequency of administra-
tion. This approach, called ‘dose-dense’ treatment, is predicated
on several related observations and hypotheses. First, fractional
cell kill has been observed in selected experimental tumour
models, suggesting that while a single cycle of effective cytotoxic
chemotherapy may not be curative, multiple cycles should be if the
cells are drug-sensitive and the duration is adequate (Skipper,
1971). Secondly, the dose-to-response relationship for some of the
most active drugs against breast cancer may not rise continually
but instead appears to reach a plateau in the higher end of the
normal dose range (Fisher et al, 1997, 1999; Henderson et al,
1998). Thirdly, prior adjuvant treatment with some drugs does not
preclude the possibility of a response upon retreatment, suggesting
that we are not eliminating all sensitive cells when we use
currently available standard agents and regimens (Valagussa et al,
1986). Fourthly, tumour regrowth may be particularly rapid when
the number of viable cells is at its lowest because of the
Gompertzian shape of the growth curve (Norton et al, 1976).
Hence, cell cycle-specific agents might be most useful if applied
quickly after a prior treatment when the cells are dividing most
rapidly. In addition, this growth pattern is consistent with the
observed results of adjuvant therapy trials in terms of their modest
impact on outcome and also with the possibility that conventional
chemotherapy renders patients much closer to complete cure than
it might otherwise seem.
Dose-density is a relative concept. A regimen standing alone
cannot really be said to be dose-dense except in comparison to
another treatment plan. Treatment with a fixed dose of drug ‘D’
every 2 weeks is therefore more dose-dense than the same drug
dose given for the same number of cycles at 3-week intervals. In
contrast, ‘dose-intensity’ is a mathematic transformation which
takes into account not only dose size but also the relative value of
individual drugs and the total duration of treatment. However, it
specifically does not account for frequency of administration and
assumes, for example, that drug ‘D’ given at dose ‘X’ once every 4
weeks has the same effect as when it is given at 1/4X weekly for
four weeks doses. In both cases the dose-intensity calculates as 
1/4X per week but the real biological effect could be quite
different, particularly if 1/4X is as cytotoxic as X. Indeed, the
observations and hypotheses described above predict that even if
dose X is four times more effective than 1/4X, it may have a lesser
overall impact than the smaller dose given more often. This is the
prime motivation behind the testing of dose-dense regimens.
The purest clinical test of dose-dense chemotherapy to date may
be the randomized trial of alternating or sequential cyclophos-
phamide, methotrexate, and 5-fluorouracil (CMF) and doxorubicin
(A) (Bonadonna et al, 1995). Over 400 women with four or more
involved axillary nodes received four cycles of doxorubicin and
eight of CMF. The less dose-dense arm utilized an alternating plan
of two cycles of CMF followed by one cycle of doxorubicin
(CCACCACCACCA) while the more dose-dense arm consisted of
all four cycles of doxorubicin followed by all eight of CMF
(AAAACCCCCCC). At 10 years of follow-up the latter remains
significantly superior. To take advantage of the hoped-for steep
dose-response relationship for cyclophosphamide, we performed a
pilot trial substituting high-dose cyclophosphamide in place of
CMF in the sequential plan. Here the dose of cyclophosphamide
was escalated and the density of treatment was increased by short-
ening the inter-treatment interval to 14 days (Hudis et al, 1999a).
This was made feasible by using granulocyte-colony stimulating
Factor. Every 14-day administration of cyclophosphamide had
been tested by the Cancer and Leukemia Group B in metastatic
disease using granulocyte macrophage-colony stimulating factor,
but the use of this regimen within weeks of high-dose doxorubicin
had be tested before a randomized trial could be started (Lichtman
et al, 1993). Based upon these results, the Southwest Oncology
group led a randomized trial (SWOG 9313) of concurrent versus
sequential doxorubicin and cyclophosphamide for patients with
0–3 involved lymph nodes, the results of which are awaited.
Based on its promising activity, paclitaxel was then added to the
sequential dose-dense regimen of doxorubicin and cyclophos-
phamide resulting in the ATC regimen comprising three courses of
each at 2-week intervals (Hudis et al, 1999b). This pilot trial also
utilized escalated doses and granulocyte-colony stimulating factor
to maintain the planned 2-week dosing intervals so that the nine
cycles of treatment were planned to require 18 weeks. Based on
the outcome of this and a second small feasibility trial, another
SWOG-coordinated randomized trial (SWOG 9623) was begun
(Hudis et al, 1996). Here dose-dense sequential doxorubicin,
paclitaxel, and cyclophosphamide (ATC) given at 2-week week
intervals is being compared to concurrent AC given for four
courses at 3-week intervals followed by ‘conventional’ high-dose
autologous stem-cell supported consolidation. This trial is open
only to patients with 4 or more involved axillary nodes and is
about halfway accrued.
Despite these trials, proof that dose-density matters, or at least
that it does at the extremes of dosing intervals which require
growth factor support, is lacking. The Cancer and Leukemia
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received four doses of doxorubicin 60 mg m–2, cyclophosphamide
600 mg m–2, and paclitaxel 175 mg m–2 with randomization
between every second (more dose-dense) or third (less dose-
dense) week treatment intervals. In addition these patients were
randomized to treatment with sequential single agents
(AAAATTTTCCCC) or concurrent AC followed by paclitaxel.
This well-controlled trial will go far in determining the real world
value of increasing the dose-density of conventional dose
chemotherapy.
The two papers included in this issue add information regarding
the feasibility of increasing dose-density. The paper by Bos et al
was designed to determine the tolerance for relatively dose-dense
CMF administered 2 weeks out of 3 for a total of six cycles as
adjuvant treatment (Bos et al, 2000). Because the interval for
‘conventional’ day 1 and 8 CMF has been 4 weeks in most prior
regimens, this represents a 25% increase in dose-density.
Alternatively, compared to ‘conventional’ intravenous CMF given
once every 3 weeks, this represents a 50% increase in dose-inten-
sity and perhaps a doubling of dose-density as well. The use of
750 mg m–2 of cyclophosphamide somewhat increases dose-inten-
sity compared to the usual dose of 600 mg m–2 used in many other
regimens. However, the aforementioned NSABP studies suggest
that this slight increase in dose and dose-intensity may not be
worthwhile (Fisher et al, 1999; 1997). Nevertheless, among these
23 otherwise-healthy relatively young women (median age 44
years) these investigators clearly demonstrate that a more dose-
dense administration of intravenous CMF is feasible if accompa-
nied by granulocyte-colony stimulating factor. They also show
that more liberal guidelines for dose-reductions and delays are
feasible with CMF, so long as one accepts the increased risks of
neutropaenia and anaemia. The most pressing question, however,
is whether the patients fare better than with other interventions.
For example, it might be that simply adding an anthracycline
and/or a taxane, or trastuzumab in appropriate cases, could yield
improved results compared to the standard CMF regimen and at
lesser cost in terms of toxicity (EBCTCG, 1998; Henderson et al,
1998) At the same time, it is worth noting that for a variety of
reasons, a significant proportion of patients is routinely treated
with CMF and a better CMF could therefore be important.
Given the apparent superiority of anthracycline-containing regi-
mens seen in the overview, the global trend towards increased use
among many subsets of patients, and the demonstration that pacli-
taxel adds to standard adjuvant AC and increases the activity of
single-agent doxorubicin, the second paper, by Lalisang et al, is
particularly timely (EBCTCG, 1998; Lalisang et al, 2000). Their
testing of the ET combination is rational given that AT was very
active in phase II studies and epirubicin may offer decreased
cardiotoxicity with no loss of efficacy (Dombernowsky et al,
1995; Gianni et al, 1995; Jain et al, 1985). Here they carefully
determined the feasibility of using granulocyte-colony stimulating
factor to reduce the interval between doses of ET. Thus, this study
tested the feasibility of increasing dose-density while maintaining
dose-level.
Subsequently, after establishing the ‘MTD’ for ET
(75/135 mg m–2) as a 10-day dosing interval, they tested 75/175
and showed this to be feasible at 10-day intervals as well. At this
interval, they judged the toxicity to be mild and, compared to
recent studies of high-dose autologous stem cell-supported
programs, they are correct. However, again toxicity was certainly
more than one would anticipate with AT or ET given at 21-day
intervals, and the worth of the shorter more dense treatment plan
must be established before considering this for general use. In
addition to the randomized studies described above, there are
several adjuvant therapy trials planned or underway which seek to
determine the benefits of more dose-intensive and dose-dense
treatment plans utilizing EC and ET in the adjuvant setting and
these must be completed before we can begin to judge the worth of
more dose-dense ET.
Do these two studies advance our field? The answer to this
question is maybe, but only moderately. For sure these studies add
to the literature showing that more dose-dense regimens are
feasible largely through the use of granulocyte-colony stimulating
factor. At least one study from the pre-growth factor era suggests
that dose-density matters, but to date no study has established that
this last increment of dose-density – the use of standard doses at
sub-3 week intervals – made feasible through the use of growth
factors, is worthwhile. Given the disappointing and somewhat
surprising results of the three large North American trials of dose
and dose-intensity for doxorubicin (Cancer and Leukemia Group
B 9344) (Henderson et al, 1998) and cyclophosphamide (Fisher et
al, 1997; 1999) we should not take for granted that increased dose-
density or dose-intensity will improve outcomes. We can hope that
this is so and we can hypothesize that this is so but we owe it to our
patients to quickly and efficiently address the value of dose-
density through appropriate randomized studies. Until then, these
approaches remain exciting but not quite ready for routine use.
REFERENCES
Bonadonna G, Zambette M and Valagussa P (1995) Sequential or alternating
doxorubicin and CMF regimens in breast cancer with more than three positive
nodes. JAMA 273: 542–547
Bos A, de Graf H, de Vries E, Piersma H and Willemse P (2000) Feasibility of a
dose-intensive CMF regimen with granulocyte colony stimulating factor as
adjuvant therapy in premenopausal patients with node-positive breast cancer.
Br J Cancer 82: 1920–1924
Dombernowsky P, Gehl J, Boesgaard M, Jensen T, Jensen B and Ejlersen B (1995)
Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin
Oncol 22: 13–17
EBCTCG (1998) Polychemotherapy for early breast cancer: an overview of the
randomised trials. Lancet 352: 930–942
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins J, Fehrenbacher L, Henry P,
Romond E, Lanier K, Davila E, Kardinal C, Laufman L, Pierce H, Abramson
N, Keller A, Hamm J, Wickerham D, Begovic M, Tan-Chiu E, Tian W and
Wolmark N (1999) Further evaluation of intensified and increased total dose of
cyclophosphamide for the treatment of primary breast cancer: findings from the
National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:
3374–3388
Fisher B, Anderson S, Wickerham D, DeCillis A, Dimitrov N, Mamounas E,
Wolmark N, Pugh R, Atkins J, Meyers F, Abramson N, Wolter J, Bornstein R,
Levy L, Romond E, Caggiano V, Grimaldi M, Jochimsen P and Deckers P
(1997) Increased intensification and total dose of cyclophosphamide in a
doxorubicin-dyclophosphamide regimen for the treatment of primary breast
cancer: findings from National Surgical Adjuvant Breast and Bowel Project 
B-22. J Clin Oncol 15: 1858–1869
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi
A, Caraceni A, Martini C, Stefanelli M, Valagussa P and Bonadonna G (1995)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women
with untreated metastatic breast cancer: High antitumor efficacy and cardiac
effects in a dose finding and sequence-finding study. J Clin Oncol 13: 2688–2699
Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J,
Cooper M, Canellos G, Borden E, Fleming G, Holland J, Graziano S,
Carpenter J, Muss H and Norton L (1998) Improved disease-free and overall
survival from the addition of sequential paclitaxel but not from the escalation
of doxorubicin dose level in the adjuvant chemotherapy of patients with node-
positive primary breast cancer. Proceedings of the Annual Meeting of the
American Society of Clinical Oncology 17: abstract 390a
1898 C Hudis
British Journal of Cancer (2000) 82(12), 1897–1899 © 2000 Cancer Research CampaignHudis C, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T,
Currie V, Moynahan M, Surbone A, Sklarin N, Robles M, Riccio L, Yao, T.-J,
Uhlenhopp M and Norton L (1996) Sequential dose-dense doxorubicin –>
paclitaxel –> cyclophosphamide is less toxic than doxorubicin –> concurrent
paclitaxel + cyclophosphamide as adjuvant therapy in resected node positive
breast cancer. Proc Am Soc Clin Onc 15: 119
Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie
V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou
M, Weiselberg L, Salvaggio R, Panageas K, Yao T and Norton L (1999a) Five-
year results of dose-intensive sequential adjuvant chemotherapy for women
with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17:
1118–1126
Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M,
Sklarin N, Fennelly D, Crown J, Surbone A, Uhlenhopp M, Riedel E, Yao T
and Norton L (1999b) Sequential dose-dense doxorubicin, paclitaxel, and
cyclophosphamide for resectable high-risk breast cancer: feasibility and
efficacy. J Clin Oncol 17: 93–100
Jain KK, Casper ES, Geller NL and Al E (1985) A prospective randomized
comparison of epirubicin and doxorubicin in patients with advanced breast
cancer. J Clin Oncol 3: 3818–3826
Lalisang R, Voest E, Wils J, Nortier H, Erdkamp F, Hillen H, Wals J, Schouten H
and Blijham G (2000) Dose-dense epirubicin and paclitaxel with G-CSF: a
study of decreasing intervals in metastatic breast cancer. Br J Cancer 82:
1914–1919
Lichtman S, Ratain M, Van Echo D, Egorin M, Budman D, Vogelzang N, Norton L,
Rosner G and Schilsky R (1993) Phase I trial of granulocyte-macrophage
colony stimulating factor (GM-CSF) plus high dose biweekly
cyclophosphamide: a CALGB Study. J Natl Cancer Inst 85: 1319–1326
Norton L, Simon R, Brereton J and Bogden A (1976) Predicting the course of
Gompertzian growth. Nature 264: 542–545
Skipper HE (1971) Kinetics of mammary tumor cell growth and implications for
therapy. Cancer 28: 1479–1499
Valagussa P, Tancini G and Bonadonna G (1986) Salvage treatment of patients
suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411
Dose-dense chemotherapy for breast cancer 1899
British Journal of Cancer (2000) 82(12), 1897–1899 © 2000 Cancer Research Campaign